Madan Jagasia | ASH 2018 | Results from the phase II REACH1 trial in patients with GvHD

By Madan Jagasia

Dec 3, 2018

Madan Jagasia | ASH 2018 | Results from the phase II REACH1 trial in patients with acute GvHD

Results from the phase II REACH1 trial in patients with GvHD

More about...

Acute graft-versus-host disease ASH 2018 REACH1

ASH 2018 | Validation study of the Minnesota Acute GvHD Risk Score

Dec 11, 2018

ASH 2018 | Validation study of the Minnesota Acute GvHD Risk Score

Dec 11, 2018

Comparison of ruxolitinib with other therapies for steroid-refractory acute GvHD

A phase III study REACH2 comparing the efficacy and safety of ruxolitinib with nine commonly used therapies in patients with glucocorticoid-refractory aGvHD

May 25, 2020

Comparison of ruxolitinib with other therapies for steroid-refractory acute GvHD

A phase III study REACH2 comparing the efficacy and safety of ruxolitinib with nine commonly used therapies in patients...

May 25, 2020

Subscribe to get the best content related to GvHD delivered to your inbox

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Madan Jagasia | ASH 2018 | Results from the phase II REACH1 trial in patients with GvHD

By Madan Jagasia

Dec 3, 2018

More about...

Related articles

Dec 11, 2018

Dec 11, 2018

May 25, 2020

May 25, 2020

Newsletter